Tempest Therapeutics to Advance In Vivo CAR T-Cell Therapy TPST-4003 into Clinical Trials by Year-End for Autoimmune Diseases like Myasthenia Gravis and Multiple Sclerosis

July 19, 2026

Biotech News Portal USA

Overview

Tempest Therapeutics announced on July 16, 2026, that its lead in vivo CAR T-cell product candidate, TPST-4003, is slated to enter clinical trials by year-end. This candidate will be evaluated in investigator-initiated trials targeting autoimmune diseases such as myasthenia gravis and multiple sclerosis. This move signifies the expansion of CAR T-cell therapy beyond oncology and a growing interest in less invasive in vivo approaches. TPST-4003 holds the potential to bring innovative treatment options to patients with autoimmune diseases, dramatically improving their quality of life.

In Depth

Key Findings

On July 16, 2026, Tempest Therapeutics announced that its lead in vivo CAR T-cell product candidate, TPST-4003, is projected to advance into clinical trials by the end of this year. This pioneering therapeutic is set to be evaluated in investigator-initiated trials specifically targeting severe autoimmune diseases such as myasthenia gravis and multiple sclerosis.

Technical / Clinical Details

Unlike conventional ex vivo CAR T-cell therapies, TPST-4003 employs an ‘in vivo’ approach, where CAR T-cells are generated and activated directly within the patient’s body. This offers a significant advantage by bypassing the complex, time-consuming, and costly ex vivo processes of cell collection, genetic modification, expansion, and reinfusion. This product candidate is designed to target self-reactive immune cells, such as specific B cells or plasma cells, which are implicated in the pathogenesis of autoimmune diseases. Myasthenia gravis and multiple sclerosis are autoimmune disorders caused by autoantibodies attacking the neuromuscular junction and the central nervous system, respectively, with current treatments largely limited to symptom management and broad immunosuppression. TPST-4003 aims to address the root cause of these diseases by directly eliminating pathogenic immune cells, potentially inducing long-term remission. Clinical trials will assess safety, tolerability, and initial indications of disease activity and functional improvement.

Background & Context

CAR T-cell therapy, initially a breakthrough in treating hematologic cancers, has seen its applications rapidly expand to solid tumors and autoimmune diseases. In the autoimmune field, the depletion of pathogenic B cells and plasma cells has shown efficacy, positioning CAR T-cell therapy as a promising therapeutic modality. However, traditional ex vivo CAR T therapies face challenges related to manufacturing complexity, access issues, and prolonged treatment timelines. Tempest Therapeutics’ in vivo CAR T approach holds the potential to overcome these obstacles, offering a simpler and more widely accessible treatment for a broader patient population. This represents a new paradigm shift in autoimmune disease treatment, garnering significant industry attention.

Strategic Significance & Outlook

The progression of TPST-4003 into clinical trials is a crucial step in validating the feasibility of in vivo CAR T-cell therapy for autoimmune diseases. If this approach proves safe and effective, it could be applicable not only to myasthenia gravis and multiple sclerosis but also to a variety of other autoimmune conditions. Successful implementation of this technology could free patients from the burden of lifelong immunosuppressive drugs, leading to significant improvements in their quality of life. Future clinical data will be paramount in shaping the future of in vivo CAR T-cell therapies and defining new directions in regenerative medicine.

Source: #

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.